Home >> Pharmaceuticals >> Food & Beverage >>

CEL-SCI Corporation - Product Pipeline Review - 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 40 | Code: MRS - 18286

CEL-SCI Corporation - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘CEL-SCI Corporation - Product Pipeline Review - 2015’, provides an overview of the CEL-SCI Corporation’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CEL-SCI Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of CEL-SCI Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CEL-SCI Corporation’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the CEL-SCI Corporation’s pipeline products

Reasons to buy

- Evaluate CEL-SCI Corporation’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CEL-SCI Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CEL-SCI Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CEL-SCI Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CEL-SCI Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CEL-SCI Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
CEL-SCI Corporation Snapshot 5
CEL-SCI Corporation Overview 5
Key Information 5
Key Facts 5
CEL-SCI Corporation - Research and Development Overview 6
Key Therapeutic Areas 6
CEL-SCI Corporation - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
CEL-SCI Corporation - Pipeline Products Glance 10
CEL-SCI Corporation - Late Stage Pipeline Products 10
Phase III Products/Combination Treatment Modalities 10
CEL-SCI Corporation - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
CEL-SCI Corporation - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
CEL-SCI Corporation - Drug Profiles 13
Leukocyte Interleukin 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
LEAPS-H1N1-DC 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CEL-1000 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CEL-2000 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Vaccine for Breast Cancer 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CEL-SCI Corporation - Pipeline Analysis 21
CEL-SCI Corporation - Pipeline Products by Target 21
CEL-SCI Corporation - Pipeline Products by Route of Administration 22
CEL-SCI Corporation - Pipeline Products by Molecule Type 23
CEL-SCI Corporation - Pipeline Products by Mechanism of Action 24
CEL-SCI Corporation - Recent Pipeline Updates 25
CEL-SCI Corporation - Dormant Projects 36
CEL-SCI Corporation - Dormant Projects 36
CEL-SCI Corporation - Company Statement 37
CEL-SCI Corporation - Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 39
Disclaimer 40

List of Tables
CEL-SCI Corporation, Key Information 5
CEL-SCI Corporation, Key Facts 5
CEL-SCI Corporation - Pipeline by Indication, 2015 7
CEL-SCI Corporation - Pipeline by Stage of Development, 2015 8
CEL-SCI Corporation - Monotherapy Products in Pipeline, 2015 9
CEL-SCI Corporation - Phase III, 2015 10
CEL-SCI Corporation - Phase I, 2015 11
CEL-SCI Corporation - Preclinical, 2015 12
CEL-SCI Corporation - Pipeline by Target, 2015 21
CEL-SCI Corporation - Pipeline by Route of Administration, 2015 22
CEL-SCI Corporation - Pipeline by Molecule Type, 2015 23
CEL-SCI Corporation - Pipeline Products by Mechanism of Action, 2015 24
CEL-SCI Corporation - Recent Pipeline Updates, 2015 25
CEL-SCI Corporation - Dormant Developmental Projects,2015 36
CEL-SCI Corporation, Subsidiaries 38

List of Figures
CEL-SCI Corporation - Pipeline by Top 10 Indication, 2015 7
CEL-SCI Corporation - Pipeline by Stage of Development, 2015 8
CEL-SCI Corporation - Monotherapy Products in Pipeline, 2015 9
CEL-SCI Corporation - Pipeline by Top 10 Target, 2015 21
CEL-SCI Corporation - Pipeline by Top 10 Route of Administration, 2015 22
CEL-SCI Corporation - Pipeline by Top 10 Molecule Type, 2015 23

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing